Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. per Koo, T, Popplewell, L, Athanasopoulos, T, Dickson, G

Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog per Koo, T, Okada, T, Athanasopoulos, T, Foster, H, Takeda, S, Dickson, G

Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. per Patel, K, Moore, SE, Dickson, G, Rossell, R, Beverley, P, Kemshead, J, Walsh, F

Protective effect of osteoarthritis against hip fracture: a paradigm for the prophylaxis of osteoporosis per Jordan, G, Loveridge, N, Bell, K, Power, J, Vedi, S, Rushton, N, Dickson, G, Reeve, J

Increased femoral neck cancellous bone and connectivity in coxarthrosis (hip osteoarthritis). per Jordan, G, Loveridge, N, Bell, K, Power, J, Dickson, G, Vedi, S, Rushton, N, Clarke, M, Reeve, J

Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α... per Koo, T, Malerba, A, Athanasopoulos, T, Trollet, C, Boldrin, L, Ferry, A, Popplewell, L, Foster, H, Foster, K, Dickson, G

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD per Pichavant, C, Aartsma-Rus, A, Clemens, P, Davies, K, Dickson, G, Takeda, S, Wilton, S, Wolff, J, Wooddell, C, Xiao, X, Tremblay, J

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. per Pichavant, C, Aartsma-Rus, A, Clemens, P, Davies, K, Dickson, G, Takeda, S, Wilton, S, Wolff, J, Wooddell, C, Xiao, X, Tremblay, J

Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In per Popplewell, L, Koo, T, Leclerc, X, Duclert, A, Mamchaoui, K, Gouble, A, Mouly, V, Voit, T, Pâques, F, Cédrone, F, Isman, O, Yáñez-Muñoz, R, Dickson, G

Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy. per Rincon, M, Sarcar, S, Danso-Abeam, D, Keyaerts, M, Matrai, J, Samara-Kuko, E, Acosta-Sanchez, A, Athanasopoulos, T, Dickson, G, Lahoutte, T, De Bleser, P, VandenDriessche, T, Chuah, M

P17-21. Using ubiquitin fusion to augment CD8+ T cell immune responses against HIV-1 antigens per Daniels R, Kwong S, Oh S, Fisher K, Klavinskis L, Bachy V, Roesen N, Harris J, Self S, Li F, Benlahrech A, Meiser A, Athanasopoulos T, Papagatsias T, Seymour L, Dickson G, Patterson S

Intra-dermal immunisation with SIV gag-based vaccines alone inhibits acquisition of SIVmac251 per Almond N, Stebbings R, Page M, Li B, Berry N, Ham C, Ferguson D, Rose N, Mee E, Stahl-Hennig C, Dickson G, Athanasapoulos T, Benlahrech A, Herath S, Meiser A, Patterson S

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy per Frank, DE, Schnell, FJ, Akana, C, El-Husayni, SH, Desjardins, CA, Morgan, J, Charleston, JS, Sardone, V, Domingos, J, Dickson, G, Straub, V, Guglieri, M, Mercuri, E, Servais, L, Muntoni, F

Adenovirus vectors induce expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 infection per Benlahrech, A, Harris, J, Meiser, A, Papagatsias, T, Hornig, J, Hayes, P, Lieber, A, Athanasopoulos, T, Bachy, V, Daniels, R, Fisher, K, Gotch, F, Klavinskis, L, Seymour, L, Logan, K, Barbagallo, R, Dickson, G, Patterson, S

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-... per Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K, Abbs, S, Garralda, M, Bourke, J, Wells, D, Dickson, G, Wood, M, Wilton, S, Straub, V, Kole, R, Shrewsbury, S, Sewry, C, Morgan, J, Bushby, K, Muntoni, F

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-... per Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K, Abbs, S, Garralda, M, Bourke, J, Wells, D, Dickson, G, Wood, M, Wilton, S, Straub, V, Kole, R, Shrewsbury, S, Sewry, C, Morgan, J, Bushby, K, Muntoni, F

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-conce... per Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C, Guglieri, M, Ashton, E, Abbs, S, Nihoyannopoulos, P, Garralda, M, Rutherford, M, McCulley, C, Popplewell, L, Graham, I, Dickson, G, Wood, M, Wells, D, Wilton, S, Kole, R, Straub, V, Bushby, K, Sewry, C, Morgan, J, Muntoni, F

Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases per Daboussi, F, Zaslavskiy, M, Poirot, L, Loperfido, M, Gouble, A, Guyot, V, Leduc, S, Galetto, R, Grizot, S, Oficjalska, D, Perez, C, Delacote, F, Dupuy, A, Chion-Sotinel, I, Le Clerre, D, Lebuhotel, C, Danos, O, Lemaire, F, Oussedik, K, Cedrone, F, Epinat, J, Smith, J, Yanez-Munoz, R, Dickson, G, Popplewell, L

Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy per Le Guiner, C, Servais, L, Montus, M, Larcher, T, Fraysse, B, Moullec, S, Allais, M, François, V, Dutilleul, M, Malerba, A, Koo, T, Thibaut, J-L, Matot, B, Devaux, M, Le Duff, J, Deschamps, J-Y, Barthelemy, I, Blot, S, Testault, I, Wahbi, K, Ederhy, S, Martin, S, Veron, P, Georger, C, Athanasopoulos, T, Masurier, C, Mingozzi, F, Carlier, P, Gjata, B, Hogrel, J-Y, Adjali, O, Mavilio, F, Voit, T, Moullier, P, Dickson, G